Background: A post marketing surveillance study was conducted to evaluate safety and efficacy of natalizumab in Swedish multiple sclerosis (MS) patients since its introduction in August 2006 until March 2010.
Methods: Patients were registered in the web-based Swedish MS-registry at 40 locations and evaluated every 6 months. Adverse events and clinical outcomes were recorded.
Results: One thousand one hundred and fifty-two patients were included (71.4% female) and 149 patients stopped treatment; the main reason was planned pregnancy. Anti-natalizumab antibodies were found in 4.5% (52 patients) of which 1.6% displayed persistent antibodies. Serious adverse events were rare, but included three cases with progressive multifocal leukoencephalopathy (PML). There were seven fatal cases, probably unrelated to the natalizumab treatment. For relapsing–remitting MS patients (n = 901), mean Expanded Disability Status Scale (EDSS, −10.7%), Multiple Sclerosis Severity Scale (MSSS, −20.4%), Multiple Sclerosis Impact Scale (MSIS-29, physical −9.9%, psychological −13.3%) and Symbol Digit Modalities Test (SDMT, +10.7%) all showed significant improvements during 24 months of treatment with natalizumab. The Swedish web-based MS quality registry proved to function as a platform for post-marketing MS drug surveillance, providing long-term data regarding drug effects and adverse events beyond clinical trials.
Conclusions: Our results indicate that natalizumab is generally well tolerated and has sustained efficacy for patients with active MS, though the risk of PML is still an important concern.
BrownBA. Natalizumab in the treatment of multiple sclerosis. Ther Clin Risk Manag2009; 5: 585–594.
2.
PolmanCHO’ConnorPWHavrdovaE. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
3.
US Food and Drug Administration. Drug Safety and Availability. http://www.fda.gov/Drugs/DrugSafety/ (Information on natalizumab – marketed as Tysabri.) Updated information: September 2009.
4.
Biogen Idec. Monthly Tysabri safety communication, May 2010, S.
5.
Swedish MS Association. Rekommendationer avseende behandling av MS med natalizumab (Tysabri). http://www.mssallskapet.se/ October 2009 [In English: Swedish MS Association.. Recommendations regarding treatment of MS with natalizumab (Tysabri). http://www.mssallskapet.se/.].
6.
RoxburghRHSeamanSRMastermanT. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology2005; 64: 1144–1151.
7.
KurtzkeJF. Clinical definition for multiple sclerosis treatment trials. Ann Neurol1994; 36(Suppl.): S73–S79.
8.
HobartJCRiaziALampingDLFitzpatrickRThompsonAJ. How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales. J Neurol Neurosurg Psychiatry2005; 76: 1539–1543.
9.
RiaziAHobartJCLampingDLFitzpatrickRThompsonAJ. Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatry2002; 73: 701–704.
10.
BenedictRHDuquinJAJurgensenS. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler2008; 14: 940–946.
11.
ParmenterBAWeinstock-GuttmanBGargNMunschauerFBenedictRH. Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test. Mult Scler2007; 13: 52–57.
12.
YaoKGagnonSAkhyaniN. Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS One2008; 3: e2028–e2028.
Bezabeh S, Flowers CM, Kortepeter C and Avigan M. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther 2010; 31(9): 1028–1035.
15.
LindaHvon HeijneAMajorEO. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med2009; 361: 1081–1087.
16.
HavrdovaEGalettaSHutchinsonM. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing–Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol2009; 8: 254–260.
TedeschiGAmatoMPD’AlessandroR. The pharmacovigilance program on natalizumab in Italy: 2 years of experience. Neurol Sci2009; 30(Suppl. 2): S163–S165.
19.
OturaiABKoch-HenriksenNPetersenTJensenPESellebjergFSorensenPS. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. Eur J Neurol2009; 16: 420–423.
20.
PutzkiNKolliaKWoodsSIgweEDienerHCLimmrothV. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. Eur J Neurol2009; 16: 424–426.
21.
OutteryckOOngagnaJCZephirH. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol2010; 257: 207–211.
22.
HobartJLampingDFitzpatrickRRiaziAThompsonA. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain2001; 124: 962–973.
23.
Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol. 2010;17(1): 31–37.
24.
GoodmanADRossmanHBar-OrA. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology2009; 72: 806–812.
25.
CalabresiPAGiovannoniGConfavreuxC. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology2007; 69: 1391–1403. . http://www.biogenidec.com/therapies_tysabri.
